DANA FIORI: Open Payments
NPI 1720311848 · DOVER, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$779 in 38 payments from 13 companies in 2025. Trend: 2023 $1,170 · 2024 $846 · 2025 $779
Food & beverage: $679Education: $100
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 14 | $190 |
| AstraZeneca Pharmaceuticals LP | 7 | $137 |
| Regeneron Healthcare Solutions, Inc. | 4 | $108 |
| SANOFI-AVENTIS U.S. LLC | 1 | $100 |
| Viatris Specialty LLC | 2 | $55 |
| Grifols USA, LLC | 2 | $34 |
| Amgen Inc. | 2 | $31 |
| Lilly USA, LLC | 1 | $28 |
| HARMONY BIOSCIENCES LLC | 1 | $27 |
| Verona Pharma, Inc. | 1 | $21 |
Products named: DUPIXENT, TRELEGY ELLIPTA, FASENRA, TEZSPIRE, NUCALA, YUPELRI, Prolastin-C Liquid, MOUNJARO.
Industry payments across DE — which companies pay providers there.
